Measuring the impact of COVID-19 on cancer survival using an interrupted time series analysis
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée à la COVID-19
Few studies have investigated the impact of the COVID-19 pandemic on cancer survival. Those that have included pandemic versus pre-pandemic comparisons that can mask differences during different periods of the pandemic such as COVID-19 waves. The objective of this study was to investigate the impact of the COVID-19 pandemic on cancer survival using an interrupted time series analysis and identify time points during the pandemic when observed survival deviated from expected survival.A retrospective population-based cohort study that included individuals diagnosed with cancer between January 2015 to September 2021 from Manitoba, Canada was performed. Interrupted time series analyses with Royston-Parmar models as well as Kaplan-Meier survival estimates and delta restricted mean survival times (RMST) at one year were used to compare survival rates for those diagnosed before and after the pandemic. Analyses were performed for eleven cancer types.Survival at one year for most cancer types was not significantly different during the pandemic compared to pre-pandemic except for individuals 50 to 74 years of age who were diagnosed with lung cancer from April to June 2021 (delta RMST: -31.6 days (95% CI: -58.3, -7.2)).With the exception of individuals diagnosed with lung cancer, the COVID-19 pandemic did not impact overall one-year survival in Manitoba. Additional research is needed to examine the impact of the pandemic on long-term cancer survival.
JNCI Cancer Spectrum 2024